HIT-Cas9: A CRISPR/Cas9 Genome-Editing Device under Tight and Effective Drug Control.
Ontology highlight
ABSTRACT: The CRISPR/Cas9 enabled efficient gene editing in an easy and programmable manner. Controlling its activity in greater precision is desired for biomedical research and potential therapeutic translation. Here, we engrafted the CRISPR/Cas9 system with a mutated human estrogen receptor (ERT2), which renders it 4-hydroxytamoxifen (4-OHT) inducible for the access of genome, and a nuclear export signal (NES), which lowers the background activity. Tight and efficient drug-inducible genome editing was achieved across several human cell types, including embryonic stem cells (ESCs) and mesenchymal stem cells (MSCs), upon vigorous optimization. Optimized terminal device, which we named hybrid drug inducible CRISPR/Cas9 technology (HIT-Cas9), delivered advantageous performances over several
SUBMITTER: Zhao C
PROVIDER: S-EPMC6178243 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA